Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Combining AOD-9604 with hyaluronic acid produced even better outcomes than either treatment alone with reduced lameness and lower cartilage degeneration scores
Healthcare providers carefully evaluate individual patient circumstances, considering factors such as kidney function, cardiovascular health, and existing medical conditions before recommending this combined approach
Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks
Not accounting for dead space
